Paul Tudor Jones Adagene Inc. Transaction History

Tudor Investment Corp Et Al

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.99 - $3.85 $2,549 - $4,931	-1,281 Reduced 4.93%	24,695 $51,000
Q3 2021 Nov 15, 2021	SELL	$12.7 - $20.68 $246,189 - $400,881	-19,385 Reduced 42.73%	25,976 $373,000
Q2 2021 Aug 16, 2021	SELL	$11.8 - $17.87 $23 - $35	-2 Reduced -0.0%	45,361 $615,000
Q1 2021 May 17, 2021	BUY	$17.0 - $29.99 $771,171 - $1.36 Million	45,363 New	45,363 $814,000

9.87M

Ticker ADAG
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,423,200
Market Cap $89M
Description
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid ...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.